Dapagliflozin Performance In Phase III Leaves Concerns, Particularly About Urinary Infections
This article was originally published in The Pink Sheet Daily
Executive Summary
Efficacy for Bristol-Myers Squibb/AstraZeneca's SGLT-2 inhibitor is arguably lackluster, but drug could still find attractive role as an add-on therapy.